-
Emergent BioSolutions Inc NEW YORK STOCK EXCHANGE INC.:EBS Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through their specialty products and contract development and manufacturing services, the company is dedicated to providing solutions that address public health threats. Through social responsibility, Emergent BioSolutions aims to build healthier and safer communities. The company aspires to deliver peace of mind to theis patients and customers so they can focus on what's most important in their lives. In working together, Emergent envisions protecting or enhancing 1 billion lives by 2030.
Location: 400 Professional Dr Ste 400, Maryland, 20879-3457, US | Website: www.emergentbiosolutions.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.08B
Cash
149.9M
Avg Qtr Burn
N/A
Short % of Float
13.43%
Insider Ownership
2.10%
Institutional Own.
59.52%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NARCAN (naloxone HCl) Details Opioid overdose | Approved Update | |
Vaxchora (pediatric) Details Cholera | Approved Quarterly sales | |
ACAM2000 Details Smallpox | Approved Quarterly sales | |
NARCAN (naloxone HCl) Details Opioid overdose | Approved Quarterly sales | |
Approved Quarterly sales | ||
CYFENDUS™ (AV7909 ) Details Anthrax | Approved Quarterly sales | |
Stabilized isoamyl nitrite (SIAN) Details Cyanide poisoning | Phase 1 Update | |
CHIKV VLP Details Chikungunya, Viral infection | Failed Discontinued | |
COVID-HIG Details COVID-19 | Failed Discontinued | |
FLU-IGIV Details Influenza | Failed Discontinued |